Overview

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-05-02

Target enrollment:

Participant gender:

Summary

A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).

Phase:

Phase 3

Details

Lead Sponsor:

Novartis
Novartis Pharmaceuticals

Collaborator:

GlaxoSmithKline

Treatments:

Aromatase Inhibitors
Hormones
Lapatinib
Trastuzumab